Skip to content

The effect of local abdominal heat therapy

The effect of local abdominal heat therapy on gavage tolerance in patients in Intensive Care Units

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220204053931N1
Enrollment
45
Registered
2022-02-09
Start date
2022-02-20
Completion date
Unknown
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gavage intolerance. Feeding difficulties

Interventions

Intervention 1: Control group: Patients will be treated routinely. ?Ampule Metoclopramide 10 mg will be administered intravenously three times a day. Intervention 2: Intervention group: In addition to
After the gavage, a second hot bag with water at a temperature of 40 ° C will be used. This intervention will continue until the gavage intolerance resolves and the gavage volume reaches the target le

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Having nasogastric / orogastric tube Routine food intake (intermittent enteral feeding with available solutions) Intolerance of enteral feeding (Gastric residual volume> 500 ml)

Exclusion criteria

Exclusion criteria: Radiotherapy and surgery in the abdominal region during the last 6 weeks Contraindications for heat therapy in the abdominal region such as cellulite, abdominal tumors, peritonitis, abdominal aneurysm, ascites Being an NPO (due to preparation for diagnostic tests or surgery) Having diarrhea (watery stools three or more times a day, 200 to 250 ml) Having fever (T> 38 º C) Hyperglycemia (BS> 200), due to its effect on peristalsis Any electrolyte disturbance, due to the effect on peristalsis Opium addiction Any chronic gastrointestinal disease (inflammatory bowel disease, gastrointestinal cancer, etc.) Any drugs affecting gastrointestinal peristalsis such as tricyclic antidepressants, NSIDs, anticholinergics, vasopressors (> 10 µg/kg/min) Acute gastrointestinal disorders at the time of the study, including bleeding Shock Discharge from the ICU or death during the intervention The patient's family members withdrawal to consent

Design outcomes

Primary

MeasureTime frame
Gavage intolerance (Gastric residual volume more than 500 milliliters in six hours). Timepoint: Before the intervention, before each gavage (8 times a day), until the treatment of gavage intolerance. Method of measurement: Lavage of gastric residual volume with syringe.

Secondary

MeasureTime frame
Abdomen circumference. Timepoint: Before the intervention, before each gavage (8 times a day), until the treatment of gavage intolerance. Method of measurement: using meter measuring tape.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Ahmadinejad

Kerman University of Medical Sciences

mehdia50@gmail.com+98 34 3223 5011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026